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Malaria control in Africa: progress but still much to do
During the past two decades, the international 
community has invested heavily in malaria 
control, especially in sub-Saharan Africa, with 
support increasing from around US$100 million in 
2000 to nearly $2 billion in 2013.1 How eﬀ ective 
has this investment been? Measurement of the 
eﬀ ect of enhanced eﬀ orts to control malaria has 
proved challenging. The main approaches used—
measurement of changes in deaths from malaria or 
clinical episodes of the infection—each have major 
methodological challenges.2 Estimates of the number 
of deaths due to malaria rely to a large extent on 
verbal autopsy, an imprecise method. Many infections 
can cause illness resembling malaria; thus, estimates 
of numbers of cases of malaria can be unreliable 
unless supported by laboratory diagnoses. Strenuous 
eﬀ orts are being made to improve these approaches; 
for example, ensuring that all reported clinical cases 
have been conﬁ rmed by a diagnostic test. However, 
continuing imprecision is shown by the major 
diﬀ erences in the number of deaths attributed to 
malaria in 2010 by WHO and the Institute of Health 
Metrics: 655 000 and 1 238 000, respectively.3,4
An alternative is measurement of changes in the 
prevalence of malaria infection detected by microscopy 
or by a rapid diagnostic test. This approach could be 
more precise because these methods are more speciﬁ c 
than verbal autopsy or clinical diagnosis of malaria. 
This approach was adopted by Abdisalan Noor and 
colleagues5 in an important new study in The Lancet. 
The association between prevalence of malaria 
infection and incidence of clinical malaria or malaria 
mortality is not linear,6 so a reduction in parasite 
prevalence cannot be assumed to be associated with 
a reduction in the number of deaths from malaria or 
cases of severe malaria. However, measurement of 
changes in parasite prevalence can provide a valuable 
way of assessing changes in the incidence of malaria 
infection over time.
Noor and colleagues collected data from 
26 746 malaria parasite prevalence surveys co vering 
3 575 418 person-observations done across Africa 
since 1980—a remarkable achievement. These data, 
together with spatially matched covariates, were used 
in a Bayesian hierarchical space–time model to derive 
estimates of the proportion of the population aged 
2–10 years with diﬀ erent levels of malaria parasitaemia 
(PfPR2–10) across Africa in 2000 and 2010. The results 
presented are both encouraging and sobering.
The encouraging news is that there has been a 
substantial reduction in the prevalence of malaria 
infection in children across most of sub-Saharan Africa 
in the decade 2000–10. Comparison of the PfPR2–10 
in 2010 with that in 2000 shows a fall in parasite 
prevalence in 40 of 44 countries in sub-Saharan Africa 
(Malawi, surprisingly, showed a slight increase), but 
that the extent of this fall varied greatly across the 
continent, with it being only modest in most highly 
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endemic countries. Although the number of people 
living in areas of hyperendemic or holoendemic 
malaria (PfPR2–10 >50%) has fallen during the decade 
from 218·6 million to 183·5 million (a 16% drop), the 
population living in areas of mesoendemic malaria 
(PfPR2–10 >10% to 50%) increased from 178·6 million to 
280·1 million (a 57% increase). The population living 
in areas with a PfPR2–10 less than 1% or with unstable 
malaria increased from 78·2 million to 128·2 million (a 
64% increase) and four countries (Cape Verde, Eritrea, 
South Africa, and Ethiopia) have joined Swaziland, 
Djibouti, and Mayotte in the group with a PfPR2–10 
less than 1% or unstable malaria, making elimination 
a feasible near-term goal in these countries. The 
reasons for this decline are not the focus of Noor 
and colleagues’ study, but they probably include 
socioeconomic changes,7 urbanisation,8 and the eﬀ ect 
of direct malaria control measures. By contrast with this 
positive news, in 2010, 57% of the population of Africa 
still lived in areas where the PfPR2–10 was 10% or higher,5 
an absence of progress that is shown in the 2000 and 
2010 endemicity maps presented in the manuscript.
The valuable analysis undertaken by Noor and 
colleagues5 has only been possible because of the 
work of many others in undertaking classical malaria 
prevalence surveys. If malaria prevalence is to be used as 
a key method to measure the eﬀ ect of control measures, 
such surveys must be continued, preferably with a 
standardised methodology and, in low transmission 
areas, with the inclusion of molecular diagnostic 
techniques that can detect the many infections that 
would otherwise be missed.9
During the past few years, there has been an 
increasing focus on malaria elimination,10 which is 
commendable because the ultimate goal of all malaria 
control programmes must be interruption of malaria 
transmission. However, Noor and colleagues5 have 
shown that, during the past decade, the reductions in 
malaria transmission that have been achieved in much 
of sub-Saharan Africa, although encouraging, have 
been only modest. Also, these gains are threatened 
by emerging resistance to the pyrethroid group of 
insecticides11 and by the potential appearance of 
artemisinin-resistant malaria parasites in Africa. 
More could be done to improve malaria control 
in high-risk countries by increasing coverage with 
proven interventions such as insecticide-treated 
nets and chemoprevention.12 However, a focus on 
elimination must not result in a reduction in support 
for development of new methods (drugs, insecticides, 
vaccines, and new approaches to vector control), and 
improved delivery methods, which will be needed 
in large areas of sub-Saharan Africa before malaria 
transmission can be reduced to the level at which 
elimination becomes a credible prospect.
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